DODGE & COX has added 1,502,198 shares of $REGN to their portfolio, per a new SEC 13F filing. This disclosure reflects the funds' holdings for the 06-30-2025 report period. You can see the fund's full portfolio on Quiver Quantitative, and also track the largest institutional owners of $REGN.
REGENERON PHARMACEUTICALS Hedge Fund Activity
We have seen 578 institutional investors add shares of REGENERON PHARMACEUTICALS stock to their portfolio, and 740 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO removed 1,718,579 shares (-30.4%) from their portfolio in Q2 2025, for an estimated $902,253,975
- DODGE & COX added 1,502,198 shares (+64.6%) to their portfolio in Q2 2025, for an estimated $788,653,950
- CAPITAL INTERNATIONAL INVESTORS removed 823,869 shares (-20.7%) from their portfolio in Q2 2025, for an estimated $432,531,225
- GAMMA INVESTING LLC removed 814,345 shares (-99.8%) from their portfolio in Q2 2025, for an estimated $427,531,125
- FMR LLC removed 600,995 shares (-7.3%) from their portfolio in Q1 2025, for an estimated $381,169,058
- TWO SIGMA ADVISERS, LP added 553,800 shares (+inf%) to their portfolio in Q1 2025, for an estimated $351,236,574
- GOLDMAN SACHS GROUP INC added 498,456 shares (+77.3%) to their portfolio in Q1 2025, for an estimated $316,135,748
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
REGENERON PHARMACEUTICALS Congressional Stock Trading
Members of Congress have traded $REGN stock 8 times in the past 6 months. Of those trades, 1 have been purchases and 7 have been sales.
Here’s a breakdown of recent trading of $REGN stock by members of Congress over the last 6 months:
- REPRESENTATIVE ROBERT BRESNAHAN has traded it 3 times. They made 1 purchase worth up to $15,000 on 05/15 and 2 sales worth up to $30,000 on 04/08, 02/25.
- REPRESENTATIVE BYRON DONALDS has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 04/10.
- REPRESENTATIVE JEFFERSON SHREVE sold up to $50,000 on 04/07.
- REPRESENTATIVE JULIE JOHNSON has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 04/01, 02/12.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
REGENERON PHARMACEUTICALS Analyst Ratings
Wall Street analysts have issued reports on $REGN in the last several months. We have seen 11 firms issue buy ratings on the stock, and 1 firms issue sell ratings.
Here are some recent analyst ratings:
- BMO Capital issued a "Outperform" rating on 08/04/2025
- Canaccord Genuity issued a "Buy" rating on 07/23/2025
- JP Morgan issued a "Overweight" rating on 06/09/2025
- Citigroup issued a "Buy" rating on 06/02/2025
- Morgan Stanley issued a "Overweight" rating on 06/02/2025
- RBC Capital issued a "Outperform" rating on 05/27/2025
- Guggenheim issued a "Buy" rating on 05/01/2025
To track analyst ratings and price targets for REGENERON PHARMACEUTICALS, check out Quiver Quantitative's $REGN forecast page.
REGENERON PHARMACEUTICALS Price Targets
Multiple analysts have issued price targets for $REGN recently. We have seen 15 analysts offer price targets for $REGN in the last 6 months, with a median target of $695.0.
Here are some recent targets:
- Srikripa Devarakonda from Truist Securities set a target price of $812.0 on 08/11/2025
- Evan David Seigerman from BMO Capital set a target price of $640.0 on 08/04/2025
- Matthew Harrison from Morgan Stanley set a target price of $761.0 on 08/04/2025
- Yatin Suneja from Guggenheim set a target price of $815.0 on 08/04/2025
- Brian Abrahams from RBC Capital set a target price of $695.0 on 08/04/2025
- John Newman from Canaccord Genuity set a target price of $850.0 on 07/23/2025
- Trung Huynh from UBS set a target price of $584.0 on 07/11/2025
Note that there may be inaccuracies in these estimates due to filing errors by the funds, parsing errors by us, or other anomalies.
Check out Quiver Quantitative's $REGN ticker page for more data.
